Literature DB >> 2491455

Bismuth accumulates in the body during treatment with tripotassium dicitrato bismuthate.

C J Gavey1, M L Szeto, C U Nwokolo, J Sercombe, R E Pounder.   

Abstract

Bismuth concentration was measured in plasma, dried leucocytes and urine in nine patients before, during and after treatment with tripotassium dicitrato bismuthate (De-Noltab 2 b.d.) for 6 weeks. During treatment there was an 8.5-fold rise in median plasma bismuth concentration (P less than 0.01), a non-significant doubling of leucocyte bismuth content, and a 349-fold rise in 24-h urinary bismuth excretion (P less than 0.01). The significantly increased urinary bismuth excretion continued for at least 3 months after cessation of treatment with tripotassium dicitrato bismuthate, indicating accumulation of bismuth during treatment with this drug.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2491455     DOI: 10.1111/j.1365-2036.1989.tb00187.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  14 in total

1.  Anomalous short plasma elimination half life in a patient intoxicated with bismuth subcitrate.

Authors:  A J McLean; S Islam; J R Lambert
Journal:  Gut       Date:  1990-09       Impact factor: 23.059

Review 2.  Helicobacter pylori and peptic ulcers: the present position.

Authors:  S Moss; J Calam
Journal:  Gut       Date:  1992-03       Impact factor: 23.059

3.  D-penicillamine does not increase urinary bismuth excretion in patients treated with tripotassium dicitrato bismuthate.

Authors:  C U Nwokolo; R E Pounder
Journal:  Br J Clin Pharmacol       Date:  1990-10       Impact factor: 4.335

Review 4.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

5.  [Pharmacokinetics of bismuth preparations in patients with gastritis and ulcer disease].

Authors:  R Raedsch; I Walter-Sack; E Weber; J Blessing
Journal:  Klin Wochenschr       Date:  1990-05-04

Review 6.  Pharmacokinetic considerations in the eradication of Helicobacter pylori.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

7.  Effects of food and formulation on the relative bioavailability of bismuth biskalcitrate, metronidazole, and tetracycline given for Helicobacter pylori eradication.

Authors:  Jean Spénard; Christian Aumais; Julie Massicotte; Jean-Sébastien Brunet; Claude Tremblay; Michael Grace; Marc Lefebvre
Journal:  Br J Clin Pharmacol       Date:  2005-10       Impact factor: 4.335

Review 8.  A risk-benefit assessment of drugs used in the eradication of Helicobacter pylori infection.

Authors:  A Hackelsberger; P Malfertheiner
Journal:  Drug Saf       Date:  1996-07       Impact factor: 5.606

Review 9.  Prescribing policy for antiulcer treatment in the elderly.

Authors:  G Bianchi Porro; M Lazzaroni
Journal:  Drugs Aging       Date:  1993 Jul-Aug       Impact factor: 3.923

10.  Comparative pharmacokinetics of bismuth from ranitidine bismuth citrate (GR122311X), a novel anti-ulcerant and tripotassium dicitrato bismuthate (TDB).

Authors:  L F Lacey; N M Frazer; O N Keene; J T Smith
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.